Asymmetric hydrogenation of pharmaceutically interesting substrates

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 6, 2003, Pages 855-875

  Lennon, Ian C ^a   Moran, Paul H ^a  

^a DOW CHEMICAL COMPANY   (United States)

Author keywords

Asymmetric enantioselective hydrogenation; Catalysts; Hydrogenation substrates; Imines; Ketones; Olefins; Pharmaceutical intermediates

Indexed keywords

2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; ALISKIREN; ALKENE DERIVATIVE; AMPA RECEPTOR ANTAGONIST; APREPITANT; BACLOFEN; BENZYL[3 [[1 (3,4 DICHLOROPHENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]PHOSPHINIC ACID; BETA AMINO ACID; CANDOXATRIL; IMINE; INOSINATE DEHYDROGENASE INHIBITOR; KETONE DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NAPROXEN; PREGABALIN; RO 67 8867; SUCCINIC ACID DERIVATIVE; TIPRANAVIR; TOLVAPTAN; UK 370106; UNCLASSIFIED DRUG; VX 148;

CATALYST; CHIRALITY; CRYSTALLIZATION; DIASTEREOISOMER; DRUG SYNTHESIS; ENANTIOMER; ENANTIOSELECTIVITY; HIGH THROUGHPUT SCREENING; HYDROGENATION; REACTION ANALYSIS; REVIEW; STEREOSPECIFICITY; TECHNOLOGY;

ALKENES; AMINO ACIDS; CHEMISTRY, PHARMACEUTICAL; GREAT BRITAIN; HETEROCYCLIC COMPOUNDS; HYDROGENATION; IMINES; KETONES; PHARMACEUTICAL PREPARATIONS; SUBSTRATE SPECIFICITY;

EID: 0346458787     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Blaser HU, Spindler F, Studer M: Enantioselective catalysis in fine chemicals production. Applied Catalysis A General (2001) 221 (1):119-143.
2. Blaser HU: Enantioselective catalysis in fine chemical production. Chem Commun (2003) (3):293-296.
3. Knowles WS: Asymmetric hydrogenations (Nobel lecture). Angew Chem Int Ed (2002) 41(12):1998-2007.
4. Noyori R: Asymmetric catalysis: Science and opportunities (Nobel lecture). Angew Chem Int Ed (2002) 41(12):2008-2022.
5. Sharpless KB: Searching for new reactivity (Nobel lecture). Angew Chem Int Ed (2002) 41(12):2024-2032.
6. Ager DJ: Asymmetric hydrogenation and other methods for the synthesis of unnatural amino acids and derivatives. Curr Opin Drug Discovery Dev (2002) 5(6):892-905.
7. Lennon IC, Pilkington CJ: The application of asymmetric hydrogenation for the manufacture of pharmaceutical intermediates: The need for catalyst diversity. Synthesis (2003) (11):1639-1642.
8. Zhang X, Tang W: New chiral ligands for enantioselective hydrogenation. Chem Rev (2003) 103(8):3029-3069.A comprehensive review on the wide range of ligands available for asymmetric hydrogenation.
9. Blaser HU, Malan C, Pugin B, Spindler F, Steiner H, Studer M: Selective hydrogenations for fine chemicals: Recent trends and new developments. Adv Synth Catal (2003) 345(1-2):103-151.
10. Singh J, Kronenthal DR, Schwinden M, Godfrey JD, Fox R, Vawter EJ, Zhang B, Kissick TP, Patel B, Mneimne O, Humora M et al: Efficient asymmetric synthesis of the vasopeptidase inhibitor BMS-189921. Org Lett (2003) 5(17):3155-3158.
11. Wang W, Yang J, Ying J, Xiong C, Zhang J, Cai C, Hruby VJ: Stereoselective synthesis of dipeptide β-turn mimetics: 7-Benzyl and 8-phenyl substituted azabicyclo[4.3.0]nonane amino acid esters. J Org Chem (2002) 67(18):6353-6360.
12. Harrison JR, Moody CJ: The Horner-Wadsworth-Emmons reaction in the synthesis of macrocyclic peptides: The Trp-His-Gly-Arg derived macrocycle of moroidin. Tetrahedron Lett (2003) 44(28):5189-5191.
13. Drexler HJ, Jingsong Y, Zhang S, Fischer C, Baumann W, Spannenberg A, Heller D: Chiral β-amino acid derivatives via asymmetric hydrogenation. Org Process Res Dev (2003) 7(3):355-361.
14. Beck G: Synthesis of chiral drug substances. Synlett (2002) 6:837-850.
15. Ashcroft CP, Challenger S, Derrick, AM, Storey R, Thomson NM: Asymmetric synthesis of an MMP-3 inhibitor incorporating a 2-alkyl succinate motif. Org Process Res Dev (2003) 7(3):362-368. Substrate synthesis can be challenging in the case of asymmetric hydrogenation. This paper describes an efficient method to produce the itaconate substrate, and a hydrogenation reaction on the kilogram-scale.
16. Cobley CJ, Lennon IC, Praquin C, Zanotti-Gerosa A, Appell RB, Goralski CT, Sutterer AC: Highly efficient asymmetric hydrogenation of 2-methylenesuccinamic acid using a Rh-DuPHOS catalyst. Org Process Res Dev (2003) 7(3):407-411. Substrate purity is one of the essential factors in attaining a highly efficient asymmetric hydrogenation process. This paper describes the dramatic effect that a low-level chloride impurity has on catalyst loading.
17. Burk MJ, de Koning PD, Grote TM, Hoekstra MS, Hoge G, Jennings RA, Kissel WS, Le TV, Lennon IC, Mulhern TA, Ramsden JA et al: An enantioselective synthesis of (S)-(+)-3-aminomethyl-5-methylhexanoic acid via asymmetric hydrogenation. J Org Chem (2003) 68(20):5731-5734. This paper describes the application of asymmetric hydrogenation on a multi-kilogram scale.
18. Hoge G: Synthesis of both enantiomers of a P-chirogenic 1,2-bisphospholanoethane ligand via convergent routes and application to rhodium-catalyzed asymmetric hydrogenation of Cl-1008 (pregabalin). J Am Chem Soc (2003) 125(34):10219-10227.
19. Bulliard M, Labour B, Lastennet J, Roussiasse S: Large-scale candoxatril asymmetric hydrogenation. Org Process Res Dev (2001) 5(4):438-441.
20. Burk MJ, Bienewald F, Challenger S, Derrick A, Ramsden JA: Me-DuPHOS-Rh-catalyzed asymmetric synthesis of the pivotal gluterate intermediate for candoxatril. J Org Chem (1999) 64(9):3290-3298.
21. Sturm T, Weissensteiner W, Spindler F: A novel class of ferrocenyl-aryl-based diphosphine ligands for Rh- and Ru-catalyzed enantioselective hydrogenation. Adv Synth Catal (2003) 345(1-2):160-164.
22. Boulton LT, Lennon IC, McCague R: Asymmetric hydrogenation of a 4,4-diaryl-3-butenoate; a novel approach to sertraline. Org Biomol Chem (2003) 1(7):1094-1096.
23. Yue TY, Nugent WA: Enantioselective hydrogenation of 3-alkylidenelactams: High-throughput screening provides a surprising solution. J Am Chem Soc (2002) 124(46):13692-13693. This paper describes the use of high-throughput screening to identify the optimum catalyst for a particularly challenging substrate.
24. Fukatsu K, Uchikawa O, Kawada M, Yamano T, Yamashita M, Kato K, Hirai K, Hinuma S, Miyamoto M, Ohkawa S: Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists. J Med Chem (2002) 45(19):4212-4221.
25. Renaud JL, Dupau P, Hay AE, Guingouain M, Dixneuf PH, Bruneau C: Ruthenium-catalyzed enantioselective hydrogenation of trisubstituted enamides derived from 2-tetralone and 3-chromanone: Influence of substitution on the amide arm and aromatic ring. Adv Synth Catal (2003) 345(1-2):230-238.
26. Goulioukina NS, Dolgina TM, Bondarenko GN, Beletskaya IP, Ilyin MM, Davankov VA, Pfaltz A: Highly enantioselective hydrogenation of α,β-unsaturated phosphonates with iridium-phosphinooxazoline complex: Synthesis of a phosphorus analogue of naproxen. Tetrahedron Asymmetry (2003) 14(10):1397-1401.
27. Noyori R, Ohkuma T: Asymmetric catalysis by architectural and functional molecular engineering: Practical chemo- and stereoselective hydrogenations of ketones. Angew Chem Int Ed (2001) 40(1):40-73. This is a comprehensive review of this state-of-the-art technology, highlighting, in particular, its chemo-, regio- and stereoselective hydrogenation capabilities.
28. Watanabe M, Murata K, Ikariya T: Practical synthesis of optically active amino alcohols via asymmetric transfer hydrogenation of functionalized aromatic ketones. J Org Chem (2002) 67(5):1712-1715. This paper demonstrates the versatility of the transfer hydrogenation technology with substituted ketones that cannot be effectively reduced by conventional methods.
29. Chaplin D, Harrison P, Henschke JP, Lennon IC, Meek G, Moran P, Pilkington CJ, Ramsden JA, Watkins S, Zanotti-Gerosa A: Industrially viable syntheses of highly enantiomerically enriched 1-aryl alcohols via asymmetric hydrogenation. Org Process Res Dev (2003) 7(1):89-94. This paper demonstrates the high degree of selectivity that can be obtained with the structurally unique ligand Xyl-PHANEPHOS, and the exceptional reactivity and productivity that can be obtained at very low catalyst loadings at the kilogram-scale.
30. Henschke JP, Burk MJ, Malan CG, Herzberg D, Peterson JA, Wildsmith AJ, Cobley CJ, Casy G: Synthesis and applications of HexaPHEMP, a novel biaryl phosphine ligand. Adv Synth Catal (2003) 345(1-2):300-307.
31. Henschke JP, Zanotti-Gerosa A, Moran P, Harrison P, Mullen B, Casy G, Lennon IC: A concise synthesis of a new xylyl-biaryl diphosphine ligand for asymmetric hydrogenation of ketones. Tetrahedron Lett (2003) 44(23):4379-4383.
32. 2(dipyridylphosphane)(1,2-diamine)] catalysts: Applications in asymmetric hydrogenation of a wide range of simple ketones. Chem Eur J (2003) 9(13):2963-2968.
33. 1 receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation. J Am Chem Soc (2003) 125(8):2129-2135.
34. 2(diamine) catalyst at extremely low catalyst loading to effect a dynamic kinetic resolution and, thus, a diastereoselective reduction of a chiral racemic cyclic ketone to a single diastereomeric product.
35. 2 receptor antagonist OPC-41061 using the catalytic asymmetric hydrogenation. Heterocycles (2002) 56(1-2):123-128.
36. Marshall JA, Bourbeau MP: Synthesis of enantioenriched propargylic alcohols related to polyketide natural products. A comparison of methodologies. Org Lett (2003) 5(18):3197-3199. This paper highlights the ability of the ligand chirality in [TsDPEN Ru Cl(4-cymene)] catalysts to control the stereoselectivity of chiral propargylic ketone hydrogenations, without apparent influence of the substrate chirality.
37. Fujii K, Maki K, Kanai M, Shibasaki M: Formal catalytic asymmetric total synthesis of fostriecin. Org Lett (2003) 5(5):733-736
38. Thakur VV, Nikalje MD, Sudalai A: Enantioselective synthesis of (R)-(-)-baclofen via Ru(II)-BINAP catalyzed asymmetric hydrogenation. Tetrahedron Asymmetry (2003) 14(5):581-586.
39. Labeeuw O, Phansvath P, Genêt JP: A short total synthesis of sulfobacin A. Tetrahedron Lett (2003) 44(34):6383-6386.
40. Ratovelomanana-Vidal V, Girard C, Touati R, Tranchier JP, Hassine BB, Genêt JP: Enantioselective hydrogenation of β-keto esters using chiral diphosphine-ruthenium complexes: Optimization for academic and industrial purposes and synthetic applications. Adv Synth Catal (2003) 345(1-2):261-274.
41. Hakogi T, Monden Y, Taichi M, Iwama S, Fujii S, Ikeda K, Katsumura S: Synthesis of sphingomyelin carbon analogues as sphingomyelinase inhibitors. J Org Chem (2002) 67(14):4839-4846.
42. Pámies O, Bäckvall JE: Combination of enzymes and metal catalysts. A powerful approach in asymmetric catalysis. Chem Rev (2003) 103(8):3247-3262.
43. Wang WB, Lu SM, Yang PY, Han XW, Zhou YG: Highly enantioselective iridium-catalyzed hydrogenation of heteroaromatic compounds, quinolines. J Am Chem Soc (2003) 125(35):10536-10537. This paper demonstrates the ability to stereoselectively reduce difficult heteroaromatic compounds to give valuable alkaloids.
44. Spindler F, Blaser HU: The highly enantioselective hydrogenation of N-diphenylphospinylketimines with cationic Rh ferrocenyl-diphosphine catalysts. Adv Synth Catal (2001) 343(1):68-70.
45. 2(diamine)] catalyst has been extended beyond simple ketones to dihydropyrrolo-benzothiadiazine dioxides.
46. 2(diamine)] protocol in the reduction of simple imines, and also the utility of chiral phospholanes as ligands in this methodology.
47. Roth P, Andersson PG, Somfai P: Asymmetric reduction of azirines; a new route to chiral aziridines. Chem Commun (2002) (16):1752-1753.
48. Abe H, Ammii H, Uneyama K: Pd-catalyzed asymmetric hydrogenation of α-fluorinated iminoesters in fluorinated alcohol: A new and catalytic enantioselective synthesis of fluoro α-amino acid derivatives. Org Lett (2001) 3(3):313-315.
49. WARNER-LAMBERT COMPANY (Burk MJ, Goel OP, Hoekstra MS, Mich TF, Mulhern TA, Ramsden JA): The asymmetric synthesis of pregabalin. WO-00155090 (2001).
50. SPEEDEL PHARMA AG (Herold P, Stutz S): Preparation of (R)-2-alkyl-3-phenylpropionic acids. WO-00202500 (2002).
51. PHARMACIA & UPJOHN COMPANY (Burk MJ, Johnson NM, Hewitt BD): Process for asymmetric hydrogenation. US-06211386 (2001).
52. MILLENNIUM PHARMACEUTICALS/WARNER-LAMBERT COMPANY (Harriman G, Carson K, Flynn DL, Solomon ME, Song Y, Trivedi BK, Roth BD, Kolz CN, Pham L, Sun KL): Functionalized heterocylces as modulators of chemokine function and methods of use therefor. WO-02072549 (2002).
53. MERCK & CO INC (Devine P, Hansen K): Process for the synthesis of (R)-1-(3,5-bis(trifluoromethyl)-phenyl)ethanol-1-ol by asymmetric transfer hydrogenation. US-06504066 (2003).
54. MERCK & CO INC (Devine PH, Hansen K): Synthesis of (R)-1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-ol by asymmetric hydrogenation. GB-02351735 (2001).
55. 2(amine)]-catalyzed hydrogenation to perform a diastereoselective reduction.
56. CIBA-GEIGY AG (Mickel SJ): Novel aminoalkanephosphinic acids and their salts. EP-00543780 (1993).
57. VERTEX PHARMACEUTICALS INC (Stamos D, Trudeau M, Bethiel S, Badia M, Saunders J): Inhibitors of IMPDH enzyme. WO-00056331 (2000).